Kota Murai

Kota Murai

Auto-generated profile, based on publicly available information

Kota Murai

National Cerebral and Cardiovascular Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in Journal of the American Heart Association
Verified
Journal Article
Closed access
TSToshiaki Suzuki
Toshiaki Suzuki
YKYu Kataoka
Yu Kataoka
MSMasayuki Shiozawa
Masayuki Shiozawa
KMKensuke Morris
Kensuke Morris
EKEri Kiyoshige
Eri Kiyoshige
TNTeruo Noguchi
Teruo Noguchi
Background: Acute myocardial infarction (AMI) infrequently occurs after acute stroke. The Heart‐brain team approach has a potential to appropriately manage this poststroke cardiovascular complication. However, clinical outcomes of AMI complicating acute stroke (AMI‐CAS) with the heart‐brain team approach have not been characterized. The current study investigated cardiovascular outcomes in patients with AMI‐CAS managed by a heart‐brain team. Methods and Results: We retrospectively analyzed 2390 patients with AMI at our institute (January 1, 2007–September 30, 2020). AMI‐CAS was defined as the occurrence of AMI within 14 days after acute stroke. Major adverse cerebral/cardiovascular events (cardiac‐cause death, nonfatal myocardial infarction, and nonfatal stroke) and major bleeding events were compared in subjects with AMI‐CAS and those without acute stroke. AMI‐CAS was identified in 1.6% of the subjects. Most AMI‐CASs (37/39=94.9%) presented ischemic stroke. Median duration of AMI from the onset of acute stroke was 2 days. Patients with AMI‐CAS less frequently received primary percutaneous coronary intervention (43.6% versus 84.7%; P <0.001) and dual‐antiplatelet therapy (38.5% versus 85.7%; P <0.001), and 33.3% of them did not receive any antithrombotic agents (versus 1.3%; P <0.001). During the observational period (median, 2.4 years [interquartile range, 1.1–4.4 years]), patients with AMI‐CAS exhibited a greater likelihood of experiencing major adverse cerebral/cardiovascular events (hazard ratio [HR], 3.47 [95% CI, 1.99–6.05]; P <0.001) and major bleeding events (HR, 3.30 [95% CI, 1.34–8.10]; P =0.009). These relationships still existed even after adjusting for clinical characteristics and medication use (major adverse cerebral/cardiovascular event: HR, 1.87 [95% CI, 1.02–3.42]; P =0.04; major bleeding: HR, 2.67 [95% CI, 1.03–6.93]; P =0.04). Conclusions: Under the heart‐brain team approach, AMI‐CAS was still a challenging disease, reflected by less adoption of primary percutaneous coronary intervention and antithrombotic therapies, with substantially elevated cardiovascular and major bleeding risks. Our findings underscore the need for a further refined approach to mitigate their ischemic/bleeding risks.

5 January 2025 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
DSDaisuke Shishikura
Daisuke Shishikura
YKYu Kataoka
Yu Kataoka
SNStephen J. Nicholls
Stephen J. Nicholls
KRKausik K. Ray
Kausik K. Ray
RPRishi Puri
Rishi Puri
MHMasaaki Hoshiga
Masaaki Hoshiga
The ongoing residual cardiovascular risks despite lowering low-density lipoprotein cholesterol (LDL-C) levels suggest the need to identify additional drivers associated with atherosclerosis. Circulating lipoprotein(a) [Lp(a)]promotes formation of foam cells via its proatherogenic properties. However, whether a lower Lp(a) level in combination with favorable LDL-C control could induce a more stable form of disease remains unknown. Near-infrared spectroscopy (NIRS) generates maximum lipid-core burden index in 4 mm (MaxLCBI4 mm) which is a histologically validated measure of lipidic plaque material in vivo. Therefore, the current study employed NIRS imaging to characterize lipidic plaque in association with LDL-C < 70 mg/dL and Lp(a) <50 mg/dL. We analyzed 439 patients with coronary artery disease (CAD) (554 de-novo target lesions receiving percutaneous coronary intervention) in the REASSURE-NIRS registry (NCT04864171). Clinical characteristics and NIRS-derived MaxLCBI4mm were compared among 4 groups according to LDL-C of 70 mg/dL and Lp(a) of 50 mg/dL. Almost one-third of study subjects (33.4%) exhibited both LDL-C < 70 mg/dL and Lp(a) <50 mg/dL. They were more likely male with a lower frequency of acute coronary syndrome and lipid lowering therapies were more frequently used in those with LDL-C < 70 mg/dL and Lp(a) <50 mg/dL. On NIRS imaging analysis, a smaller MaxLCBI4mm (P < .001) and a lower frequency of MaxLCBI4mm ≥400 (P = .001) were observed in those with both LDL-C < 70 mg/dL and Lp(a) <50 mg/dL. On multivariable logistic regression analysis, the coexistence of these 2 lipid controls showed an approximately 70% lower risk (adjusted odds ratio: 0.30; 95% confidence interval: 0.13-0.68) of MaxLCBI4mm ≥400 compared with the reference group (LDL-C ≥ 70 mg/dL and Lp(a) ≥50 mg/dL). Our findings suggest circulating Lp(a) as a potential therapeutic target to stabilize coronary atherosclerosis in CAD patients who achieved LDL-C < 70 mg/dL.

1 May 2023 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
YKYu Kataoka
Yu Kataoka
SNStephen J. Nicholls
Stephen J. Nicholls
RPRishi Puri
Rishi Puri
SKSatoshi Kitahara
Satoshi Kitahara
EKEri Kiyoshige
Eri Kiyoshige
TNTeruo Noguchi
Teruo Noguchi
Background: Intravascular imaging has shown better response of coronary atheroma to statin-mediated lowering of low-density lipoprotein cholesterol in women. However, its detailed mechanism remains to be determined yet. Modifiability of coronary atheroma under lipid-lowering therapies is partly driven by lipidic plaque component. Given a smaller plaque volume in women, lipidic plaque features including their density may differ between sex. Therefore, the current study sought to characterize sex-related differences in the density of lipidic plaque. Methods: We analyzed 1429 coronary lesions (culprit/nonculprit lesions=825/604) in 758 coronary artery disease patients (men/women=608/150) from the REASSURE-NIRS multicenter registry (Revelation of Pathophysiological Phenotypes of Vulnerable Lipid-Rich Plaque on Near-Infrared Spectroscopy). Total atheroma volume at 4-mm segment, maximum 4-mm-lipid-core burden index, and lipid plaque density index (=maximum 4-mm-lipid-core burden index/total atheroma volume at 4-mm segment) on near-infrared spectroscopy/intravascular ultrasound imaging at culprit and nonculprit lesions were compared in men and women. Results: Statin and high-intensity statin were used in 72.4 ( P =0.81) and 22.9% ( P =0.32) of study subjects, respectively. Women exhibited a smaller adjusted total atheroma volume at 4-mm segment (culprit lesions: 50.3±0.4 versus 54.2±0.3mm 3 , P <0.001, nonculprit lesions: 31.5±3.0 versus 44.4±2.1mm 3 , P <0.001), whereas their adjusted maximum 4-mm-lipid-core burden index did not differ between sex (culprit lesions: 544.7±29.9 versus 501.7±19.1, P =0.11, nonculprit lesions: 288.8±26.7 versus 272.7±18.9, P =0.51). Furthermore, a greater adjusted lipid plaque density index was observed in women (culprit lesions: 18.2±0.9 versus 9.8±0.6, P <0.001, nonculprit lesions: 23.0±2.0 versus 7.8±1.4, P <0.001). These adjustments of total atheroma volume at 4-mm segment, maximum 4-mm-lipid-core burden index, and lipid plaque density index included age, body mass index, hypertension, dyslipidemia, diabetes, smoking, a history of myocardial infarction and chronic kidney disease, low-density lipoprotein cholesterol level, statin and ezetimibe use, vessel volume, and hospital unit. The aforementioned plaque features consistently existed in both acute coronary syndrome and stable coronary artery disease subjects. Conclusions: Women harbored greater condensed lipidic plaque features, accompanied by smaller atheroma volume. These observations indicate potentially better modifiable disease in women, which underscores the need to intensify their lipid-lowering therapies for further improving their outcomes. Registration: URL: https://www.clinicaltrials.gov/ ; Unique identifier: NCT04864171

28 July 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
KMKota Murai
Kota Murai
MFMasashi Fujino
Masashi Fujino
TITakamasa Iwai
Takamasa Iwai
KSKenichiro Sawada
Kenichiro Sawada
HMHideo Matama
Hideo Matama
TNTeruo Noguchi
Teruo Noguchi

14 July 2022 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
KMKota Murai
Kota Murai
YKYu Kataoka
Yu Kataoka
SNStephen J. Nicholls
Stephen J. Nicholls
RPRishi Puri
Rishi Puri
YNYuriko Nakaoku
Yuriko Nakaoku
TNTeruo Noguchi
Teruo Noguchi

24 May 2026 in European Heart Journal
Verified
Journal Article
Open access
YKYu Kataoka
Yu Kataoka
KRKausik K Ray
Kausik K Ray
SNStephen Nicholls
Stephen Nicholls
AKAya Katasako-Yabumoto
Aya Katasako-Yabumoto
SKSatoshi Kitahara
Satoshi Kitahara
TNTeruo Noguchi
Teruo Noguchi
Background and Aims: Current guidance recommends better LDL-C control in patients with elevated Lp(a) as Lp(a) lowering therapies are unavailable. Whether risks attributable to Lp(a) are mitigated in patients with CAD who achieved LDL-C <55 mg/dL remains unknown. Methods: Multicentre retrospective observational study analysed 1581 Japanese patients with CAD [Lp(a)-JAPAN: jRCT1050260016]. Risk of MACE (cardiac-caused death + nonfatal MI + coronary revascularization in non-culprit segments) was compared according to Lp(a) levels (<30, ≥30, and <50 mg/dL and ≥50 mg/dL) and amongst LDL-C strata (<55 mg/dL vs ≥55 mg/dL) 8 weeks after PCI. Results: During the 5.1-year observation amongst patients with LDL-C ≥55mg/dL (n=1069), MACE occurred in 21.3% with risk of MACE increasing with Lp(a) levels (3.9, 7.9, and 11.0 events per 100 person-years for <30, ≥30, and <50 mg/dL and ≥50 mg/dL, log-rank p<0.001). Amongst those with LDL-C <55mg/dL (n=512), the proportion with MACE was lower overall (4.3%, p<0.001). However, elevated Lp(a) levels still identified those at higher risk of MACE (1.4, 4.7, and 7.5 events per 100 person-years in Lp(a) <30, ≥30, and <50 mg/dL and ≥50 mg/dL, p<0.001). Standardized 5-year MACE rate was over twice and five times higher in patients with Lp(a) ≥30 and <50 mg/dL (17.0%: adjusted HR = 3.80, 95% CI = 1.78–8.11, p<0.001) and ≥50 mg/dL (33.4%: adjusted HR = 6.90, 95% CI = 3.53–13.46, p<0.001) compared to Lp(a) <30 mg/dL (5.0%), respectively. The ROC analyses identified Lp(a) ≥28.2 mg/dL as the threshold for MACE (AUC = 0.68, p<0.001). Conclusions: Whilst lower achieved LDL-C attenuates in part the risk from Lp(a), elevated Lp(a) levels still associate with worse cardiovascular outcomes. The Lp(a) threshold amongst Japanese patients with CAD at risk of recurrent events appears lower than in Caucasian populations which merits further evaluation.